@article{article, title  = {{DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5103 }},

 year = {{2022}},

 month = {{6}},

 author = {{Niazi T and McBride SM and Williams S and Davis ID and Stockler MR and Martin AJ and Bracken K and Roncolato F and Horvath L and Sengupta S and Martin J et al}},

 doi = {{10.1200/jco.2022.40.16_suppl.tps5103}},

 volume = {{40}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{16_suppl}},

 pages = {{TPS5103-TPS5103}},

 note = {{Accessed on 2024/12/22}}}